FMP

FMP

Enter

LRMR - Larimar Therapeutics...

photo-url-https://images.financialmodelingprep.com/symbol/LRMR.png

Larimar Therapeutics, Inc.

LRMR

NASDAQ

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.

8.92 USD

-0.2 (-2.24%)

About

ceo

Dr. Carole S. Ben-Maimon M.D.

sector

Healthcare

industry

Biotechnology

exchange

NASDAQ

Description

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.

CIK

0001374690

ISIN

US5171251003

CUSIP

517125100

Address

Three Bala Plaza East

Phone

844 511 9056

Country

US

Employee

42

IPO Date

Jun 19, 2014

Key Executives

page loading card
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep